TScan Therapeutics (TCRX) Cash & Current Investments (2020 - 2026)

TScan Therapeutics (TCRX) has 7 years of Cash & Current Investments data on file, last reported at $128.1 million in Q1 2026.

• On a quarterly basis, Cash & Current Investments fell 49.12% year-over-year to $128.1 million in Q1 2026; TTM through Mar 2026 was $128.1 million, a 49.12% decrease from a year earlier, with the FY2025 full-year figure at $152.4 million, down 47.47% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $128.1 million, down from $152.4 million in the prior quarter.
• Over the last five years, Cash & Current Investments for TCRX reached as high as $297.7 million in Q2 2024 and fell as low as $95.6 million in Q1 2023.
• Historically, Cash & Current Investments has averaged $187.8 million across 5 years, with a median of $184.5 million in 2025.
• Across the five-year window, Cash & Current Investments surged 70.26% in 2024 and sank 49.12% in 2026, its largest moves.
• Year by year, Cash & Current Investments stood at $120.0 million in 2022, then surged by 60.0% to $192.0 million in 2023, then jumped by 51.06% to $290.1 million in 2024, then tumbled by 47.47% to $152.4 million in 2025, then retreated by 15.98% to $128.1 million in 2026.
• Per Business Quant data, the three most recent Cash & Current Investments figures were $128.1 million in Q1 2026, $152.4 million in Q4 2025, and $184.5 million in Q3 2025.